Abstract
The effects of sulphinpyrazone administration on the metabolic and renal clearances of theophylline in man were investigated. Sulphinpyrazone increased total plasma theophylline clearance by 22%. This was the sum of increases in metabolic clearances by 3-demethylation (32%), 1-demethylation (30%) and 8-oxidation (22%) and of a decrease in renal clearance (27%). It is proposed that sulphinpyrazone has differential effects on at least two forms of cytochrome P-450 inhibiting one enzyme or group of enzymes which metabolises tolbutamide, phenytoin and S(-)warfarin and inducing a form (or forms) which metabolises theophylline, antipyrine and R(+)warfarin.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bailey R. R., Reddy J. Potentiation of warfarin action by sulphinpyrazone. Lancet. 1980 Feb 2;1(8162):254–254. doi: 10.1016/s0140-6736(80)90736-9. [DOI] [PubMed] [Google Scholar]
- Birkett D. J., Miners J. O., Attwood J. Secondary metabolism of theophylline biotransformation products in man--route of formation of 1-methyluric acid. Br J Clin Pharmacol. 1983 Jan;15(1):117–119. doi: 10.1111/j.1365-2125.1983.tb01475.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Foenander T., Birkett D. J., Miners J. O., Wing L. M. The simultaneous determination of theophylline, theobromine and caffeine in plasma by high performance liquid chromatography. Clin Biochem. 1980 Jun;13(3):132–134. doi: 10.1016/s0009-9120(80)90819-x. [DOI] [PubMed] [Google Scholar]
- Gallus A., Birkett D. Sulphinpyrazone and warfarin: a probable drug interaction. Lancet. 1980 Mar 8;1(8167):535–536. doi: 10.1016/s0140-6736(80)92783-x. [DOI] [PubMed] [Google Scholar]
- Grygiel J. J., Birkett D. J. Cigarette smoking and theophylline clearance and metabolism. Clin Pharmacol Ther. 1981 Oct;30(4):491–496. doi: 10.1038/clpt.1981.193. [DOI] [PubMed] [Google Scholar]
- Grygiel J. J., Birkett D. J. Effect of age on patterns of theophylline metabolism. Clin Pharmacol Ther. 1980 Oct;28(4):456–462. doi: 10.1038/clpt.1980.188. [DOI] [PubMed] [Google Scholar]
- Grygiel J. J., Wing L. M., Farkas J., Birkett D. J. Effects of allopurinol on theophylline metabolism and clearance. Clin Pharmacol Ther. 1979 Nov;26(5):660–667. doi: 10.1002/cpt1979265660. [DOI] [PubMed] [Google Scholar]
- Miners J. O., Foenander T., Wanwimolruk S., Gallus A. S., Birkett D. J. Interaction of sulphinpyrazone with warfarin. Eur J Clin Pharmacol. 1982;22(4):327–331. doi: 10.1007/BF00548401. [DOI] [PubMed] [Google Scholar]
- Miners J. O., Foenander T., Wanwimolruk S., Gallus A. S., Birkett D. J. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination. Eur J Clin Pharmacol. 1982;22(4):321–326. doi: 10.1007/BF00548400. [DOI] [PubMed] [Google Scholar]
- O'Reilly R. A. Stereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man. Circulation. 1982 Jan;65(1):202–207. doi: 10.1161/01.cir.65.1.202. [DOI] [PubMed] [Google Scholar]
- O'Reilly R. A., Trager W. F., Motley C. H., Howald W. Stereoselective interaction of phenylbutazone with [12C/13C]warfarin pseudoracemates in man. J Clin Invest. 1980 Mar;65(3):746–753. doi: 10.1172/JCI109722. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pond S. M., Birkett D. J., Wade D. N. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):573–579. doi: 10.1002/cpt1977225part1573. [DOI] [PubMed] [Google Scholar]
- Walter E., Staiger C., de Vries J., Zimmermann R., Weber E. Induction of drug metabolizing enzymes by sulfinpyrazone. Eur J Clin Pharmacol. 1981;19(5):353–358. doi: 10.1007/BF00544586. [DOI] [PubMed] [Google Scholar]